

Supplementary Online Content

Said JT, Liu M, Talia J, et al. Risk factors for the development of bullous pemphigoid in US patients receiving immune checkpoint inhibitors. *JAMA Dermatol*. Published online April 13, 2022. doi:10.1001/jamadermatol.2022.0354

eTable. Best Overall Responses to Immune Checkpoint Inhibitor Therapy Across ICI-BP Cases and Controls

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Best Overall Responses to Immune Checkpoint Inhibitor Therapy Across ICI-BP Cases and Controls

Characteristics	All (N=105)	BP (N=35)	Non-BP dAE (N=33)	No dAE (N=37)	BP vs All Controls	BP vs Non-BP dAE	BP vs No dAE
<u>BOR</u>					0.16	0.75	0.01
CR	37 (35.2)	15 (42.9)	16 (48.5)	6 (16.2)			
PR	35 (33.3)	14 (40.0)	9 (27.3)	12 (32.4)			
SD	15 (14.3)	2 (5.7)	3 (9.1)	10 (27.0)			
PD	18 (17.1)	4 (11.4)	5 (15.2)	9 (24.3)			
<u>BOR, simplified</u>					0.03	0.55	0.003
Response	72 (68.6)	29 (82.9)	25 (75.8)	18 (48.6)			
No response	33 (31.4)	6 (17.1)	8 (24.2)	19 (51.4)			

ICI-BP patients, in terms of BOR, had similar distributions of ICI response outcomes as patients with non-BP dAEs. When controls were not adjusted for non-BP dAEs, ICI-BP patients were more likely to have a response (CR or PR) than patients who did not have ICI-BP, regardless of other dAEs (p=0.03).

Compared to patients with no dAEs (BP or otherwise), patients with ICI-BP were very significantly more likely to have a response (CR or PR) (p=0.003). All p-values were calculated from four-by-two (BOR) or two-by-two (BOR, simplified) Fisher's exact tests, between the BP cases and indicated comparator group.

Abbreviations: BOR = best overall response. BP = bullous pemphigoid. CR = complete response. dAE = dermatologic immune-related adverse event. ICI = immune checkpoint inhibitor. ICI-BP = immune checkpoint inhibitor-induced bullous pemphigoid. PD = progression of disease. PR = partial response. SD = stable disease.